Fresenius Medical Care presents its new research and innovation for kidney care at European Renal Association Congress 2025

Rhea-AI Summary

Fresenius Medical Care (FMS), the global leader in renal disease products and services, will present groundbreaking research at the 62nd European Renal Association Congress in Vienna. The company will showcase 52 abstracts focusing on critical care, fluid management, hemodiafiltration, and AI applications in kidney care. Key highlights include a Top Abstract award for research on arterial oxygen saturation during dialysis, CONVINCE trial findings showing hemodiafiltration's benefits over hemodialysis, and innovative AI-based dietary recommendations for dialysis patients. The presentations demonstrate FME's commitment to data-driven insights and real-world evidence to improve outcomes for 4.2 million global dialysis patients. The company operates 3,675 dialysis clinics serving approximately 299,000 patients worldwide.

Insights

Healthcare Research Analyst

Fresenius showcases research advancements in dialysis techniques, with promising hemodiafiltration outcomes potentially improving future kidney disease treatment.

Fresenius Medical Care's presentations at the ERA Congress represent significant contributions to evidence-based kidney care advancement. The company's impressive portfolio of 52 research abstracts demonstrates substantial investment in clinical research across critical nephrology areas.

The standout CONVINCE trial analysis provides compelling evidence that hemodiafiltration (HDF) leads to slower health decline compared to traditional hemodialysis in specific patient populations. This finding has significant clinical implications, as the data shows improvements in physical function, cognitive function, pain management, and social participation with HDF. Clinical teams may need to reconsider treatment modality selection based on these outcomes.

Their research on arterial oxygen saturation instability during dialysis, which earned Top Abstract recognition, applies AI to identify potential connections to sleep apnea. This represents an important advancement in understanding intradialytic hypoxemia, a common but often overlooked complication.

The study correlating fluid overload changes to hospitalization risk provides actionable insights for clinical management. Similarly, their confirmation that shorter treatment times increase mortality reinforces the importance of optimizing therapy duration – a modifiable factor that could significantly impact patient survival.

Their AI-based recipe recommendation system demonstrates a holistic approach to care, addressing the nutritional challenges faced by dialysis patients through innovative technology. This solution could improve dietary adherence, a persistent challenge in kidney disease management.

As the market leader with 3,675 dialysis clinics serving approximately 299,000 patients globally, Fresenius's research initiatives maintain their position at the forefront of evidence-based kidney care innovation while potentially influencing treatment protocols across the industry.

• Key abstract presentations showcase significant advancements in clinical care, artificial intelligence, and fluid management, demonstrating Fresenius Medical Care's commitment to improving patient outcomes.
• Top Abstract recognition for "Prevalence and Patterns of Intradialytic Arterial Oxygen Saturation Instability: Observations in a Large U.S. Hemodialysis Cohort," presented in the "Dialysis" category.
• CONVINCE trial analysis links hemodiafiltration to slower health decline and better quality of life in key dialysis patient groups.

BAD HOMBURG, Germany, May 30, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, presents new research and innovations at the 62nd Congress of the European Renal Association (ERA), June 4-7 in Vienna, Austria highlighting the company's growing emphasis on data-driven insights and real-world evidence to advance patient care and improve outcomes and quality of life for people with kidney disease worldwide.

"Our highlighted research demonstrates our continued drive to innovate in kidney care," said Frank Maddux, MD, Global Chief Medical Officer at Fresenius Medical Care AG. "To further enhance our commitment to improving patient outcomes globally, our latest work focuses on Home, Critical Care and In-Center HD, and high-volume hemodiafiltration in particular. ERA is an essential platform to reinforce collaboration and drive the future of nephrology."

Fresenius Medical Care's Global Medical Office and the company's kidney disease think tank, the Renal Research Institute (RRI), present 52 abstracts spanning critical areas of nephrology, including critical care, fluid management, hemodiafiltration (HDF), and the use of artificial intelligence (AI) in patient care.

Key presentations include:

• Prevalence and Patterns of Intradialytic Arterial Oxygen Saturation Instability: Observations in a Large U.S. Hemodialysis Cohort: Awarded Top Abstract for Young Authors in the "Dialysis" category, this study, authored by RRI's Andrea Nandorine Ban, uses AI to evaluate patterns of arterial oxygen saturation during dialysis, highlighting the prevalence of intradialytic hypoxemia and its potential link to sleep apnea.
• Health Status in Different Subgroups of People Receiving Hemodiafiltration Versus Hemodialysis for Renal Replacement Therapy: A subgroup analysis of the CONVINCE randomized controlled trial examines whether the slower decline in self-reported health status with hemodiafiltration (HDF) versus hemodialysis (HD) varies by age, sex, dialysis vintage, diabetes, cardiovascular disease, and vascular access type. Results highlight particular improvements in physical and cognitive function, pain interference, and social participation with HDF.
• Impact of Fluid Overload Changes Within the First Six Months of Dialysis on Hospitalization During a Two-year Follow-up: Using data collected from the Body Composition Monitor, a validated whole-body bioimpedance spectroscopy device, this study evaluates how early changes in fluid overload in hemodialysis (HD) and HDF patients are associated with hospitalization risk over a two-year period.
• Delivered Hemodialysis Treatment Time and Mortality Risk: A Retrospective Analysis: Shorter treatment times have been shown to increase mortality in hemodialysis (HD) patients. This analysis reinforces treatment time as a modifiable factor and encourages clinical teams to optimize therapy durations to improve survival outcomes for HD patients.
• Novel AI-Based Recipe Recommendation System for Dialysis Patients Using Retrieval-Augmented Generation: Leveraging Retrieval-Augmented Generation and OpenAI models, this innovation provides dialysis patients with personalized, scalable dietary recommendations, supporting better nutritional management.

In addition to these presentations, FME leaders and researchers will also be available onsite at Booth #460 to discuss research insights, clinical collaborations, and innovations in kidney care.

To learn more about FME's presence at ERA, please click here.

About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.2 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,675 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 299,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the company's website at www.freseniusmedicalcare.com.

The information in this document is provided as is and no guarantee or warranty is given that the information is fit for any particular purpose. The user thereof uses the information at its sole risk and liability. The opinions expressed in the document are of the authors only and in no way reflect the European Commission's opinions. 

The CONVINCE study was exclusively supported by the European Commission Research & Innovation, Horizon 2020, Call H2020-SC1-2016-2017 under the topic SC1-PM-10-2017: Comparing the effectiveness of existing healthcare interventions in the adult population (grant no 754803). 

Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.

Media contact
Kirsten Stratton
T +1 781 929 8096
kirsten.stratton@freseniusmedicalcare.com 

Christine Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com 

Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609 2601
dominik.heger@freseniusmedicalcare.com 

www.freseniusmedicalcare.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-presents-its-new-research-and-innovation-for-kidney-care-at-european-renal-association-congress-2025-302469225.html

SOURCE Fresenius Medical Care Holdings, Inc.

FAQ

What research will Fresenius Medical Care (FMS) present at ERA Congress 2025?

Fresenius Medical Care will present 52 abstracts covering critical care, fluid management, hemodiafiltration, and AI applications in kidney care, including a Top Abstract on arterial oxygen saturation patterns during dialysis.

What are the key findings from the CONVINCE trial analysis presented by FMS?

The CONVINCE trial analysis shows that hemodiafiltration leads to slower health decline compared to hemodialysis, with particular improvements in physical and cognitive function, pain management, and social participation.

How many dialysis patients and clinics does Fresenius Medical Care (FMS) serve globally?

Fresenius Medical Care serves approximately 299,000 patients through 3,675 dialysis clinics worldwide, with about 4.2 million patients regularly undergoing dialysis treatment globally.

What new AI technology is Fresenius Medical Care introducing for dialysis patients?

Fresenius Medical Care is introducing a novel AI-based recipe recommendation system using Retrieval-Augmented Generation and OpenAI models to provide personalized dietary recommendations for dialysis patients.

When and where will the 62nd European Renal Association Congress 2025 take place?

The 62nd European Renal Association Congress will take place from June 4-7, 2025, in Vienna, Austria.